Table 5.

Treatment efficacy in all patients and in NSCLC patients

Investigator-assessed responseAll patients (N = 34)NSCLC all (N = 27)NSCLC weekly bortezomib (N = 15)*NSCLC twice-weekly bortezomib (N = 12)
PRNSCLC (9)9 (33%)6 (40%)3 (25%)
Urothelial cell cancer (3)
ACUP (1)
SD§NSCLC (15)15 (56%)8* (53%)7 (58%)
Urothelial cell cancer (1)
Pancreatic cancer (1)
PDNSCLC (3)3 (11%)1 (7%)2 (17%)
Hepatocellular cancer (1)
  • Abbreviations: PR, partial response; SD, stable disease; PD, progressive disease.

  • * Ten patients treated at 1.0 mg/m2; five patients treated at 1.3 mg/m2 bortezomib.

  • One patient treated at 0.7 mg/m2; 11 patients treated at 1.0 mg/m2 bortezomib.

  • Identified as breast carcinoma at a later stage.

  • § Including a NSCLC with a partial response that could not be confirmed because of death due to fatal bleeding during broncoscopic procedure.